Is vitamin D deficiency behind the scenes for high incidence of Giant cell tumor amongst the Indian population? Unraveling the vitamin D – RANKL association
- 21 December 2018
- journal article
- research article
- Published by Elsevier in Medical Hypotheses
- Vol. 123, 67-71
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspectsTumor Biology, 2015
- Regulation of gene expression by 1,25-dihydroxyvitamin D3 in bone cells: exploiting new approaches and defining new mechanismsBoneKEy Reports, 2014
- Modern Interpretation of Giant Cell Tumor of Bone: Predominantly Osteoclastogenic Stromal TumorClinics in Orthopedic Surgery, 2012
- Evidence for osteocyte regulation of bone homeostasis through RANKL expressionNature Medicine, 2011
- Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Giant Cell Tumor of BoneThe American Journal of Pathology, 2000
- Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand FamiliesEndocrine Reviews, 1999
- RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in OsteoclastogenesisBiochemical and Biophysical Research Communications, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell functionNature, 1997
- OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATIONEndocrinology, 1988